Deepu Madduri, MD

Articles

CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to Know

November 10th 2020

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Dr. Madduri on the Results of the CARTITUDE-1 Trial in Multiple Myeloma

December 9th 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

Dr. Madduri on the Potential Impact of CAR T-Cell Therapy in Multiple Myeloma

August 3rd 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the potential impact of CAR T-cell therapy in multiple myeloma.

Dr. Madduri on Challenges in Transplant-Eligible Patients With Myeloma

April 13th 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses challenges in the transplant-eligible myeloma population.

Dr. Madduri on the Standard of Care for Transplant Eligible Patients With Myeloma

January 8th 2019

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the standard of care for transplant eligible patients with multiple myeloma.

Dr. Madduri on Treatment After CAR T Cells in Myeloma

December 11th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Dr. Madduri Discusses Checkpoint Inhibitors in Myeloma

September 20th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma

August 22nd 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

Dr. Madduri on SWOG S0777 in Multiple Myeloma

July 16th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.